[en] These last few years, new advances in technologies and modern insulin regimens have improved diabetes care for children and adolescents and have led to the definition of new therapeutic goals.Au cours de ces dernières années, les nouvelles avancées technologiques et thérapeutiques ont marqué la prise en charge du diabète de l’enfant et de l’adolescent amenant ainsi à définir de nouveaux objectifs thérapeutiques.
Radermecker RP, Philips JC. Avancées thérapeutiques et technologiques dans la prise en charge du patient diabétique de type 1 adulte. Rev Med Liege 2020, 75:399-405.
Fath M, Danne T, Biester T, et al. Faster-Acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2017;18:903-10.
Bode BW, Iotova V, Kovarenko M, et al. Efficacy and safety of fast-Acting insulin aspart compared with insulin aspart, both in combination with insulin degludec, in children and adolescents with type 1 diabetes : The ONSET 7 trial. Diabetes Care 2019;42:1255-62.
Thalange N, Deeb L, Iotova V, et al. Insulin degludec in combination with bolus insulin apart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes 2015;16:164-76.
Thalange N, Biester T, Danne T. Clinical use of degludec in children and adolescents with T1D : A narrative review with fictionalized case reports. Diabetes Ther 2019;10:1219-37.
Danne T, Tamborlane WV, Malievsky O, et al. Insulin glargine 300 U/ml (Gla-300) provides effective glycemic control in youths with type 1 diabetes (T1D): The EDITION Junior study. Poster presented at the 45th Annual Conference of the International Society for Pediatric and Adolescent Diabetes 2019;Boston:USP240;2.
Rodbard D. Continuous glucose monitoring : A review of recent studies demonstrating improves glycemic outcomes. Diabetes Technol Ther 2017;19:25-37.
Massa GG, Gys I, Op't Eyndt A, et al. Evaluation of the FreeStyle libre flash glucose monitoring system in children and adolescents with type1 diabetes. Horm Res Paediatr 2018;89:189-99.
Burckhardy MA, Roberts A, Smith GJ, et al. The use of continuous glucose monitoring with remote monitoring improves psychosocial measures in parents of children with type 1 diabetes. A randomized crossover trial. Diabetes Care 2018;41:2641-3.
De Ridder F, den Brinker M, De Block C. The road from intermittently scanned continuous glucose monitoring to hybrid closed-loop systems. Part B : results from randomized controlled study. Ther Adv Endocrinol Metab 2019;10:1-17.
Biester T, Kordonouri O, Holder M, et al. Let the algorithm do the work. Reduction of hypoglycemia using sensor-Augmented pump therapy with predictive insulin suspension (SmartGuard) in pediatric type 1 diabetes patients. Diabetes Technol Ther 2017;19:173-82.
Massa GG, Gys I, Bevilacqua E, et al. Comparison of flash glucose monitoring with real time continuous glucose monitoring in children and adolescents with type 1 diabetes treated with continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2019;152:111-8.
Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, et al. Safety evaluation of the MiniMed 670G system in children 7-13 years of age with type1 Diabetes. Diabetes Technol Ther 2019;21:11-20.
Salehi P, Roberts AJ, Kim GJ. Efficacy and safety of reallife usage of MiniMed 670G automode in children with type 1 diabetes less than 7 years old. Diabetes Technol Ther 2019;21:448-51.
DiMeglio LA, Acerini E, Codner E, et al. ISPAD clinical practice consensus guidelines 2018 : glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes 2018;19:105-14.
Rayan CM, van Duinkerken E, Rosano C. Neurocognitive consequences of diabetes. Am Psychol 2016;71:563-76.
Haynes A, Hermann JM, Miller KM, et al. Severe hypoglycemia rates are not associated with HbA1c: A cross-sectional analysis of 3 contemporary pediatric diabetes registry databases. Pediatr Diabetes 2017;18:643-50.
Beck RW, Connor CG, Mullen DM, et al. The fallacy of average : how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 2017;40:994-9.
Lind M, Pivodic A, Svensson AM, et al. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes : Swedish population based cohort study. BMJ 2019;366:l4894.
Battelino T, Danne T, Bergenstal R, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593-603.
